Veracyte, Inc. (VCYT) is a Biotechnology company in the Healthcare sector, currently trading at $34.30. It has a SharesGrow Score of 70/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of VCYT = $48.21 (+40.6% from the current price, the stock appears undervalued). Analyst consensus target is VCYT = $45 (+29.7% upside).
Valuation: VCYT trades at a trailing Price-to-Earnings (P/E) of 37.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.61.
Financials: revenue is $517M, +20.4%/yr average growth. Net income is $66M, growing at +67.9%/yr. Net profit margin is 12.8% (healthy). Gross margin is 69.6% (+3.9 pp trend).
Balance sheet: total debt is $40M against $1.3B equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 8.15 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $1.4B.
Analyst outlook: 13 / 20 analysts rate VCYT as buy (65%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 70/100 (Pass), Future 67/100 (Pass), Income 55/100 (Partial).
